Drugs / Toca FC
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04089163 | Dec 2019 → Jan 2022 | urinary bladder cancer | Tocagen Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02598011 | Jan 2017 → Nov 2022 | malignant glioma | Tocagen Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02576665 | Jul 2016 → May 2019 | colorectal cancer, head and neck cancer, high grade astrocytic tumor, lymphoma +7 | Tocagen Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01156584 | Jul 2010 → Aug 2016 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma | Tocagen Inc. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02414165 | Nov 2015 → May 2019 | anaplastic astrocytoma, glioblastoma | Tocagen Inc. | Terminated | Missed primary Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01985256 Background | Feb 2014 → Mar 2016 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma | Tocagen Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Toca FC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02598011 ↗ |
| Route | Oral | “oral Toca FC” NCT01985256 ↗ |